rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    DERM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Journey Medical Corporation Q3 2026 Earnings Call Summary
      Nov 13Yahoo FinanceDERM
      Journey Medical Corp (DERM) Q3 2026 Earnings Call Highlights: Emrosi Momentum Drives Revenue ...

      Journey Medical Corp (DERM) posted 8% revenue growth to $19 million and adjusted EBITDA of $3.5 million, fueled by Emrosi demand and a major national formulary win set for 2027.

      Nov 13Yahoo FinanceDERM
      Journey Medical earnings missed by $0.07, revenue fell short of estimates
      Nov 12Investing.comDERM
      What Journey Medical (DERM) Said on Its Q3 Earnings Call
      Nov 12Yahoo FinanceDERM
      Journey Medical (DERM) Reports Q3 Earnings: What Key Metrics Have to Say
      Nov 12Yahoo FinanceDERM
      Earnings call transcript: Journey Medical’s Q3 2026 loss narrows as stock rises after hours
      Nov 12Investing.comDERM
      Journey Medical Corporation (DERM) Reports Q3 Loss, Lags Revenue Estimates
      Nov 12Yahoo FinanceDERM
      Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
      Nov 12Yahoo FinanceDERM
      Earnings To Watch: Journey Medical Corp (DERM) Q3 2026 -- GF Value Sees 76% Upside
      Nov 11Yahoo FinanceDERM
      Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
      Nov 5Yahoo FinanceDERM
      Will Journey Medical Corporation (DERM) Report Negative Q3 Earnings? What You Should Know
      Nov 4Yahoo FinanceDERM
      Are Options Traders Betting on a Big Move in Journey Medical Stock?

      Investors need to pay close attention to DERM stock based on the movements in the options market lately.

      Sep 21Yahoo FinanceDERM
      Journey Medical: A Small Pharma With A Large Growth Opportunity (NASDAQ:DERM)

      Journey Medical (DERM) is rated Buy, driven by Emrosi’s rapid prescription growth and expanding payer coverage.

      Sep 19Seeking AlphaDERM
      Journey Medical at H.C. Wainwright: emrosi drives growth
      Sep 14Investing.comDERM
      Journey Medical Corporation to Participate in September 2026 Investor Conferences

      SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences. Details of

      Sep 8Yahoo FinanceDERM

      This is the newest page. Registered accounts read further back.